Skip to main content

Bristol-Myers Value Stock - Dividend - Research Selection


ISIN: US1101221083, WKN: 850501

Market price date: 06.07.2022
Market price: 76,22 USD

Bristol-Myers Fundamental data and company key figures of the share

Annual reports in USD
Key figures 10-02-2022
Cash flow
Net operating cash flow
Capital Expenditures -973.000.000
Free cash flow 15.233.999.872
Balance sheet
Total Equity
Liabilities & Shareholders equity 109.314.000.000
Income statement
Net income 6.994.000.000
Eps (diluted) 3,120
Diluted shares outstanding
Net sales/revenue 46.385.000.000

Fundamental ratios calculated on: 06-07-2022

Key figures 06-07-2022
Cash flow
P/C 10,56
P/FC 11,23
Balance sheet
Income statement
Div. Yield2,64%

Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.

Market Capitalization171.113.906.176,00 USD
CountryUnited States
IndicesMSCI World Index,S&P 500
Raw Data SourceUS GAAP in Millionen USD
Stock Split2001-08-07,1000000.0000/951777.0000; 1999-03-01,2.0000/1.0000; 1997-03-03,2.0000/1.0000; 1987-06-10,2.0000/1.0000; 1983-05-27,2.0000/1.0000; 1977-05-31,2.0000/1.0000

Description of the company

Bristol-Myers Squibb Company (BMS) is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis. It operates in BioPharmaceuticals. Its products are sold worldwide, primarily to wholesalers, retail pharmacies, hospitals, government entities and the medical profession. It manufactures products in the United States (U.S.), Puerto Rico and in 6 foreign countries. In February 2012, it acquired Inhibitex, Inc. (Inhibitex). In August 2012, the Company announced the acquisition of Amylin Pharmaceuticals, Inc. In August 2012, Synergy Pharmaceuticals Inc announced that it signed an Asset Purchase Agreement with the Company and acquired the assets related to FV-100, an orally available nucleoside analogue, being developed for the treatment of shingles.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources::,,


2022 Second Half Outlook: Hungover Like Its 2000

Comparing today to the year 2000, how much further downside should we expect in stocks? What is likely to unfold on the economic front?

6 Stocks Hedge Funds Love in a Recession

6 stocks hedge funds love in a recession, including the top 3 holdings from Michael Burry and Leon Cooperman.

Bristol Myers Squibb : Statement of Changes in Beneficial Ownership (Form 4)

Ownership Submission FORM 4 Check this box if no longer... | July 5, 2022

The All-Weather Portfolio: Saying Farewell To A Terrible Quarter

While Q2 proved significantly more challenging than Q1, the All-Weather Portfolio remains positive for the year. Read more about the all-weather portfolio here.

Lyra Therapeutics appoints Nieman as Chief Medical Officer

Lyra Therapeutics (LYRA) ... LYRA, BMY, TEVA, BAYRY

A Buyout-Driven Pair Trade: Buy Aurinia, Sell Merck (Or Seagen If You Must)

The most recent two hottest potatoes in the biotech arena are Aurinia and Seagen. See why we think AUPH should be on the long side and Merck in the short side.

Carillon Tower: “Bristol-Myers Squibb (BMY) Entered Into Accelerated Share Repurchase Agreements”

Carillon Tower Advisers, an investment management firm, published its “Carillon Clarivest Capital Appreciation Fund” first quarter 2022 investor letter – a copy of which can be downloaded here. At the start of the quarter, the Carillon ClariVest Capital Appreciation Fund (the “Fund”), as compared to the Russell 1000® Growth Index, was most overweight in the information […]

IN BRIEF: Evotec selects oncology project to develop for beLAB2122

Looking for stock market analysis and research with proves results? offers in-depth financial research with over 30years of proven results.

Wide Moat ETF Adds Financials, Quits Coca-Cola And Big Tobacco, Keeps Faith In Tech

The VanEck Morningstar Wide Moat ETF invests in US companies that possess wide economic moats per Morningstar's methodology. MOAT was not immune to the market's retreat in Q2.

'Minions: The Rise of Gru' tops $108 million as parents flock back to cinemas, kids in tow

"Minions: The Rise of Gru" generated more than $108 million in ticket sales during its domestic opening weekend.